Updates

Explore Medicines360’s latest news and resources

Press Releases

Actavis and Medicines360 Announce Publication of ACCESS IUS Efficacy and Safety Study of LILETTA™ (Levonorgestrel-Releasing Intrauterine System) 52 mg in Contraception

The study found that LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg, is 99.45% effective for the prevention of pregnancy for up to three years of use in women aged 16-35 regardless of race, parity (previous births), or body mass index (BMI). The ACCESS IUS trial is still ongoing and will evaluate the efficacy and safety of LILETTA for up to seven years of use.

Read More >
Press Releases

Actavis and Medicines360 Announce U.S. Availability of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years

Actavis plc (NYSE: ACT), a leading global pharmaceutical company and leader in women’s health care, and Medicines360, a nonprofit women’s health pharmaceutical company, announced today that LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg is now available in the U.S. for use by women to prevent pregnancy for up to three years.

Read More >
Press Releases

Actavis and Medicines360 Announce FDA Approval of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women’s health pharmaceutical company, today announced the approval of LILETTA™ (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration (FDA) for use by women to prevent pregnancy for up to three years. LILETTA is placed in the uterus by a healthcare professional and works by continuously releasing levonorgestrel, a progestin, to prevent pregnancy.

Read More >
Press Releases

Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert™ IUD

Medicines360, a non-profit women’s health pharmaceutical company, and Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360’s New Drug Application (NDA) for Levosert™ (levonorgestrel), a hormonal intrauterine contraceptive (IUC) for use by women to prevent pregnancy.

Read More >
Press Releases

Actavis and Medicines360 Announce Partnership to Advance Women’s Access to Affordable IUDs

Medicines360, a non-profit pharmaceutical company, and Actavis, Inc., a leading global specialty pharmaceutical company, today announced a historic partnership to support Medicines360’s mission to reduce cost as a barrier to accessing women’s birth control. The Medicines360 and Actavis partnership will make the IUD available in the U.S. commercially and at a very low price in U.S.public sector clinics. As part of this agreement, Actavis has licensed the U.S. commercial rights for the Medicines360 LNG20 Intrauterine Device (IUD).

Read More >